L
L. Wang
Researcher at MedImmune
Publications - 20
Citations - 1514
L. Wang is an academic researcher from MedImmune. The author has contributed to research in topics: Sifalimumab & Systemic lupus erythematosus. The author has an hindex of 11, co-authored 20 publications receiving 1190 citations. Previous affiliations of L. Wang include AstraZeneca.
Papers
More filters
Journal ArticleDOI
Anifrolumab, an Anti–Interferon-α Receptor Monoclonal Antibody, in Moderate-to-Severe Systemic Lupus Erythematosus
Richard Furie,Munther A. Khamashta,Joan T. Merrill,Victoria P. Werth,Kenneth C. Kalunian,Philip Brohawn,G. Illei,Jorn Drappa,L. Wang,Stephen Yoo +9 more
TL;DR: To assess the efficacy and safety of anifrolumab, a type I interferon (IFN) receptor antagonist, in a phase IIb, randomized, double‐blind, placebo‐controlled study of adults with moderate‐to‐severe systemic lupus erythematosus (SLE).
Journal ArticleDOI
Sifalimumab, an anti-interferon-α monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study
Munther A. Khamashta,Joan T. Merrill,Victoria P. Werth,Victoria P. Werth,Richard Furie,Kenneth C. Kalunian,G. Illei,Jorn Drappa,L. Wang,Warren Greth +9 more
TL;DR: The efficacy and safety of sifalimumab were assessed in a phase IIb, randomised, double-blind, placebo-controlled study of adults with moderate to severe active systemic lupus erythematosus (SLE).
Journal ArticleDOI
Sifalimumab, a human anti-interferon-α monoclonal antibody, in systemic lupus erythematosus: a phase I randomized, controlled, dose-escalation study.
Michelle Petri,Daniel J. Wallace,Alberto Spindler,Vishala Chindalore,Kenneth C. Kalunian,Eduardo Mysler,C. Michael Neuwelt,Gabriel Robbie,Wendy I. White,Brandon W. Higgs,Yihong Yao,L. Wang,D Ethgen,Warren Greth +13 more
TL;DR: In this article, the authors evaluated the safety and tolerability of multiple intravenous (IV) doses of sifalimumab in adults with moderate-to-severe systemic lupus erythematosus (SLE).
Journal ArticleDOI
A CD40L-targeting protein reduces autoantibodies and improves disease activity in patients with autoimmunity.
Jodi L. Karnell,Albulescu Marius,Stacey Drabic,L. Wang,Rachel Moate,Manuel Baca,Vaheh Oganesyan,Michele Gunsior,Thomas Thisted,Li Yan,Jing Li,Ximing Xiong,Steven Eck,Melissa de los Reyes,Isharat Yusuf,Katie Streicher,Ulf Müller-Ladner,David Howe,Rachel Ettinger,Ronald Herbst,Jorn Drappa +20 more
TL;DR: The generation and clinical results of a CD40L binding protein, VIB4920, which lacks an Fc domain, therefore avoiding platelet-related safety issues observed with earlier monoclonal antibody therapeutics that targetedCD40L are reported.
Journal ArticleDOI
Anifrolumab effects on rash and arthritis: impact of the type I interferon gene signature in the phase IIb MUSE study in patients with systemic lupus erythematosus.
Joan T. Merrill,Richard Furie,Victoria P. Werth,Munther A. Khamashta,Jorn Drappa,L. Wang,G. Illei,Raj Tummala +7 more
TL;DR: Anifrolumab treatment was associated with improvements versus placebo in specific SLE features of arthritis and rash using measures of different stringency, driven by robust data in the prevalent IFNGS test–high population.